- Home
- Products
- Customized ADCs
- S. aureus ClfA
- Anti-S. aureus ClfA (Tefibazumab)-MC-MMAF ADC
Anti-S. aureus ClfA (Tefibazumab)-MC-MMAF ADC (CAT#: ADC-W-2134)
This ADC product is comprised of an anti-S. aureus ClfA monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- S. aureus ClfA
- Alternative Names
- S. aureus ClfA
- Overview
- S. aureus may occur as a commensal on skin; it also occurs in the nose frequently (in about a third of the population) and the throat less commonly; S. aureus can infect other tissues when barriers have been breached. S. aureus infections may spread through contact with pus from an infected wound, skin-to-skin contact with an infected person by producing hyaluronidase that destroys tissues, and contact with objects such as towels, sheets, clothing, or athletic equipment used by an infected person. Deeply penetrating S. aureus infections can be severe. ClfA is a 92 kDa surface protein identified from S. aureus. ClfA is responsible for the fibrinogen-dependent c1umping of bacteria.
- Overview
- Humanized Anti-S. aureus ClfA IgG1-kappa antibody, Tefibazumab
- Generic name
- Tefibazumab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CCR5 (PRO 140)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-767)
- Anti-ITGAE (clone M290)-MCC-DM1 ADC (CAT#: ADC-W-534)
- Anti-TNFRSF9 (Urelumab)-SMCC-DM1 ADC (CAT#: ADC-W-1892)
- Anti-CD3E (Ertumaxomab)-SPDB-DM4 ADC (CAT#: ADC-W-2301)
- Anti-E. coli Stx2B (Urtoxazumab)-MC-MMAF ADC (CAT#: ADC-W-2140)
- Anti-CD4 (Priliximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-865)
- Anti-MST1R (Narnatumab)-SPDB-DM4 ADC (CAT#: ADC-W-1599)
- Anti-ACVR2B (Bimagrumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-655)
- Anti-C-kit (9P3)-SPDB-DM4 ADC (CAT#: ADC-W-077)
- Anti-PDGFR (Tovetumab)-SPDB-DM4 ADC (CAT#: ADC-W-1713)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-2134. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-2136 | Anti-S. aureus ClfA (Tefibazumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2133 | Anti-S. aureus ClfA (Tefibazumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-2135 | Anti-S. aureus ClfA (Tefibazumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-2137 | Anti-S. aureus ClfA (Tefibazumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2132 | Anti-S. aureus ClfA (Tefibazumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-452 | Anti-CD70 (clone 1F6)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-518 | Anti-TM4SF1 ( clone 2A7A)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
| ADC-AA-063 | Anti-HIgG(Fab)-N-MMAF ADC | Noncleavable linkers | MMAF |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2585 | Anti-EGFR (Zalutumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
